工程3D打印的口香糖装满了儿科使用的甲福林
Karla J Santamaría1,2, Brayan J Anaya1, Aikaterini Lalatsa3,4
1Pharmaceutics and Food Technology Department, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain.
Gels (Basel, Switzerland)
|October 25, 2024
概括
3D打印为儿童创造了有吸引力的甲胺,改善了粘附力. 这种半固体挤出技术为儿科药物输送提供了一个有希望的,可定制的方法.
科学领域:
- 制药技术 制药技术 制药技术
- 材料科学 材料科学 材料科学
- 儿科医学 儿科医学
背景情况:
- 开发有吸引力和有效的药物输送系统对于儿科治疗坚持至关重要.
- 3D打印为创建可定制和患者友好的剂量形式提供了一种新的方法.
研究的目的:
- 使用半固体挤出 (SSE) 3D打印生产250毫克的甲福林儿科.
- 通过设计方法来比较3D打印和造方法.
- 为了评估3D打印的口香糖的物理特性和药物释放概况.
主要方法:
- 用甲福林制备药品墨水,用于室温SSE3D打印.
- 利用通过设计的质量方法来优化制造过程.
- 对比3D打印和传统造方法用于生产.
主要成果:
- 成功制备了一种含有甲胺的药用墨水,具有最佳的流动性.
- 与造相比,3D打印的皮表现出优越的牢固性和持续的药物释放.
- 这些3D打印的具具有可取的纹理和外观,模仿商业产品.
结论:
- 半固体挤出3D打印使得成功制造了用于治疗儿科糖尿病的无糖甲福林.
- 这种3D打印方法是一种易于用于临床实践的可翻译方法.
- 开发的片增强了口感,并确保为儿科患者提供有效的药物.
更多相关视频
07:55Pancreatic Tissue-Derived Extracellular Matrix Bioink for Printing 3D Cell-Laden Pancreatic Tissue Constructs
Published on: December 13, 2019
10.9K
09:18Feeding Experimentation Device FED: Construction and Validation of an Open-source Device for Measuring Food Intake in Rodents
Published on: February 21, 2017
8.1K
相关概念视频
Oral Hypoglycemic Agents: Glinides
142
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
142
Oral Hypoglycemic Agents: Biguanides and Glitazones
176
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
176
